Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel M Verbeek

Showing results (211-220 of 237) with videos related to

Pageof 24
Sort By:
Orphanet Journal of Rare Diseases|May 28, 2020
Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH<sub>4</sub>) deficienciesThomas Opladen, Eduardo López-Laso, Elisenda Cortès-Saladelafont, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 12, 2021
Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter studyPetra Steinacker, Emily Feneberg, Steffen Halbgebauer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 11, 2019
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD studyAlberto Lleó, Daniel Alcolea, Pablo Martínez-Lage, et al.
Orphanet Journal of Rare Diseases|August 8, 2020
Correction to: Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficienciesThomas Opladen, Eduardo López-Laso, Elisenda Cortès-Saladelafont, et al.
Biomarkers in Medicine|August 25, 2012
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42Niklas Mattsson, Ingrid Zegers, Ulf Andreasson, et al.
Journal of Alzheimer'S Disease : JAD|October 16, 2018
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid BiomarkersMafalda Ramos de Matos, Catarina Ferreira, Sanna-Kaisa Herukka, et al.
Frontiers in Neurology|November 4, 2015
The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative DiseasesBabette L R Reijs, Charlotte E Teunissen, Nikolai Goncharenko, et al.
Journal of Alzheimer'S Disease : JAD|November 30, 2020
White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid BiomarkersLinda J C van Waalwijk van Doorn, Mohsen Ghafoorian, Esther M C van Leijsen, et al.
European Journal of Neurology|May 7, 2022
Concordance of cerebrospinal fluid real-time quaking-induced conversion across the European Creutzfeldt-Jakob Disease Surveillance NetworkNeil McKenzie, Gabriele Piconi, Audrey Culeux, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 30, 2013
CSF biomarker variability in the Alzheimer's Association quality control programNiklas Mattsson, Ulf Andreasson, Staffan Persson, et al.
Pageof 24

Showing results (211-220 of 237) with videos related to

Sort By:
Pageof 24
Orphanet Journal of Rare Diseases|May 28, 2020
Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH<sub>4</sub>) deficienciesThomas Opladen, Eduardo López-Laso, Elisenda Cortès-Saladelafont, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 12, 2021
Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter studyPetra Steinacker, Emily Feneberg, Steffen Halbgebauer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 11, 2019
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD studyAlberto Lleó, Daniel Alcolea, Pablo Martínez-Lage, et al.
Orphanet Journal of Rare Diseases|August 8, 2020
Correction to: Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficienciesThomas Opladen, Eduardo López-Laso, Elisenda Cortès-Saladelafont, et al.
Biomarkers in Medicine|August 25, 2012
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42Niklas Mattsson, Ingrid Zegers, Ulf Andreasson, et al.
Journal of Alzheimer'S Disease : JAD|October 16, 2018
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid BiomarkersMafalda Ramos de Matos, Catarina Ferreira, Sanna-Kaisa Herukka, et al.
Frontiers in Neurology|November 4, 2015
The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative DiseasesBabette L R Reijs, Charlotte E Teunissen, Nikolai Goncharenko, et al.
Journal of Alzheimer'S Disease : JAD|November 30, 2020
White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid BiomarkersLinda J C van Waalwijk van Doorn, Mohsen Ghafoorian, Esther M C van Leijsen, et al.
European Journal of Neurology|May 7, 2022
Concordance of cerebrospinal fluid real-time quaking-induced conversion across the European Creutzfeldt-Jakob Disease Surveillance NetworkNeil McKenzie, Gabriele Piconi, Audrey Culeux, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 30, 2013
CSF biomarker variability in the Alzheimer's Association quality control programNiklas Mattsson, Ulf Andreasson, Staffan Persson, et al.
Pageof 24